Clarian Health Ventures has invested an undisclosed amount of money in NeoChord Inc., a Minneapolis company that’s developing a treatment for mitral-valve regurgitation.
The treatment is based on technology first developed at Mayo Clinic and has since received funding by angel investors with ties to Indianapolis, Clarian said in a press release. The technology has been successfully used in two Mayo patients, and the company plans additional pre-clinical and human clinical trials over the next year.
Mitral-value regurgitation prohibits proper blood flow within the heart and is currently treated by open heart surgery.
NeoChord CEO John Seaberg lived in Indianapolis for several years and served as an executive at defibrillator maker Guidant Corp. before he started NeoChord.